Compare HIMX & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIMX | FTRE |
|---|---|---|
| Founded | 2001 | 1996 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2006 | 2023 |
| Metric | HIMX | FTRE |
|---|---|---|
| Price | $9.08 | $9.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.39 |
| AVG Volume (30 Days) | ★ 3.6M | 1.7M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | $14.94 | N/A |
| Revenue Next Year | $7.79 | $2.96 |
| P/E Ratio | $14.99 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $5.66 | $3.97 |
| 52 Week High | $12.00 | $18.67 |
| Indicator | HIMX | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 59.53 | 41.95 |
| Support Level | $8.24 | $9.13 |
| Resistance Level | $9.74 | $11.22 |
| Average True Range (ATR) | 0.70 | 0.70 |
| MACD | 0.19 | 0.19 |
| Stochastic Oscillator | 41.27 | 55.16 |
Himax Technologies Inc is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The majority of the firm's revenue is derived from the Driver Integrated Circuit segment. It offers display driver ICs and timing controllers used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, virtual reality (VR) devices, and many other consumer electronics devices. It also designs and provides controllers for touch sensor displays, in-cell Touch and Display Driver Integration single-chip solutions, LED driver ICs, power management ICs, and scaler products for monitors and projectors. Geographically, it generates the majority of its revenue from China.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.